CompletedNCT00094926
About this title
A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.
Read the official source — NCT00094926What is this study about?Researchers compared Risperdal Consta and placebo, tracking side effects to assess safety in adults with bipolarity.
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarityMedication studyAges 18–70
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT06273774
Official study titleA Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Participants With Bipolar I Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockBipolarityMedication studyAges 18–60
- Countries
- United States
- Sponsor
- Merck Sharp & Dohme LLC
CompletedNCT05406440
What is this study about?Researchers compared Elpipodect and placebo, tracking side effects to assess safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Merck Sharp & Dohme LLC
CompletedNCT07053345
Official study titleAn Interventional, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of Esketamine Nasal Spray in Korean Participants With Treatment-Resistant Depression(TRD)
This study has finished and is no longer accepting participants.
Multiple locations, including Goyang Si Gyeonggi DoDepressionMedication studyAges 18–64
- Countries
- South Korea
- Sponsor
- Janssen Korea, Ltd., Korea
WithdrawnNCT03852160
Official study titleA Randomized, Double-Blind, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly-dosed Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
This study was withdrawn before enrollment.
Location not clearly listedDepressionMedication studyAges 18–74
- Countries
- Sponsor
- Janssen-Cilag International NV
CompletedNCT04599855
Official study titleA Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamDepressionMedication studyAges 18+
- Countries
- United States
- Sponsor
- Janssen Research & Development, LLC
CompletedNCT00791232
Official study titleA Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Phase 1 Study to Compare the Tolerability of OROS Paliperidone (Extended Release) With Immediate-release (IR) Risperidone in Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00999219
Official study titleFK199B (Zolpidem MR Tablet) Phase III Clinical Study - A Double-Blind, Crossover, Comparative Polysomnographic Study Using Zolpidem (Myslee®) as a Positive Control in Patients With Insomnia, Excluding Patients With Schizophrenia or Manic-Depressive Psychosis
This study has finished and is no longer accepting participants.
Multiple locations, including ChūbuBipolarityMedication studyAges 20–65
- Countries
- Japan
- Sponsor
- Astellas Pharma Inc
CompletedNCT03033069
Official study titleA Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Brexpiprazole (1 - 3 mg/Day) as Monotherapy or as Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including TuscaloosaPTSDMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT01541371
What is this study about?Researchers studied Paliperidone ER to find out how it affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
CompletedNCT02006628
Official study titleA Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including CzeladźSchizophreniaMedication studyAges 18–65
- Countries
- United Kingdom, Poland, Romania
- Sponsor
- Jazz Pharmaceuticals
CompletedNCT00297388
About this title
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
Read the official source — NCT00297388Official study titleA 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–70
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
